Pacira Biosciences (NASDAQ:PCRX)‘s stock had its “hold” rating reaffirmed by stock analysts at Cowen in a research report issued to clients and investors on Thursday, November 7th, AnalystRatings.com reports. They presently have a $41.00 target price on the stock. Cowen’s price target would suggest a potential downside of 4.47% from the stock’s previous close.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.
A number of other research analysts have also recently commented on the stock. Zacks Investment Research raised shares of Pacira Biosciences from a “sell” rating to a “hold” rating and set a $47.00 target price on the stock in a research report on Friday, August 2nd. Jefferies Financial Group set a $60.00 price target on shares of Pacira Biosciences and gave the stock a “buy” rating in a research note on Tuesday, October 8th. BMO Capital Markets cut their price target on shares of Pacira Biosciences from $46.00 to $43.00 and set a “market perform” rating on the stock in a research note on Friday, August 9th. BTIG Research started coverage on shares of Pacira Biosciences in a research note on Wednesday, November 6th. They set a “buy” rating and a $56.00 target price on the stock. Finally, Stifel Nicolaus set a $42.00 target price on shares of Pacira Biosciences and gave the stock a “hold” rating in a research note on Friday, August 9th. One analyst has rated the stock with a sell rating, seven have given a hold rating and six have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $52.55.
Shares of PCRX traded up $0.34 during midday trading on Thursday, hitting $42.92. The stock had a trading volume of 557,100 shares, compared to its average volume of 434,464. Pacira Biosciences has a 1 year low of $34.64 and a 1 year high of $50.30. The company has a debt-to-equity ratio of 0.98, a current ratio of 3.95 and a quick ratio of 3.32. The stock’s 50 day moving average is $39.85 and its 200 day moving average is $41.24. The firm has a market cap of $1.78 billion, a PE ratio of 148.00, a price-to-earnings-growth ratio of 1.91 and a beta of 1.13.
Pacira Biosciences (NASDAQ:PCRX) last announced its earnings results on Thursday, November 7th. The company reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.13 by $0.35. The company had revenue of $104.69 million for the quarter, compared to analysts’ expectations of $104.88 million. Pacira Biosciences had a net margin of 0.55% and a return on equity of 10.19%. The firm’s quarterly revenue was up 25.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.31 EPS. As a group, equities research analysts expect that Pacira Biosciences will post 0.71 earnings per share for the current fiscal year.
In other news, VP Lauren Bullaro Riker sold 5,000 shares of the stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $43.59, for a total value of $217,950.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 5.80% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently bought and sold shares of PCRX. Amundi Pioneer Asset Management Inc. acquired a new position in shares of Pacira Biosciences in the 1st quarter valued at about $65,000. Cortina Asset Management LLC increased its holdings in shares of Pacira Biosciences by 14.5% in the 2nd quarter. Cortina Asset Management LLC now owns 208,471 shares of the company’s stock valued at $9,066,000 after acquiring an additional 26,427 shares during the last quarter. Boston Private Wealth LLC bought a new stake in shares of Pacira Biosciences in the 2nd quarter valued at approximately $217,000. First Hawaiian Bank bought a new stake in shares of Pacira Biosciences in the 2nd quarter valued at approximately $404,000. Finally, Legacy Capital Partners Inc. increased its holdings in shares of Pacira Biosciences by 2.2% in the 2nd quarter. Legacy Capital Partners Inc. now owns 48,573 shares of the company’s stock valued at $2,112,000 after acquiring an additional 1,025 shares during the last quarter. Hedge funds and other institutional investors own 99.13% of the company’s stock.
About Pacira Biosciences
Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure.
Featured Story: What is the outlook for the FAANG stocks?